Last reviewed · How we verify
bOPV (two dose)
bOPV (bivalent oral polio vaccine) stimulates the immune system to produce antibodies against poliovirus types 1 and 3, providing protection against poliomyelitis.
bOPV (bivalent oral polio vaccine) stimulates the immune system to produce antibodies against poliovirus types 1 and 3, providing protection against poliomyelitis. Used for Prevention of poliomyelitis caused by poliovirus types 1 and 3.
At a glance
| Generic name | bOPV (two dose) |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Drug class | Live attenuated vaccine |
| Target | Poliovirus types 1 and 3 |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
bOPV is a live attenuated vaccine containing weakened strains of poliovirus types 1 and 3. When administered orally, it replicates in the intestinal tract and triggers both mucosal and systemic immune responses, generating neutralizing antibodies and cellular immunity against these poliovirus serotypes. The two-dose regimen ensures adequate immunogenicity and protective antibody titers.
Approved indications
- Prevention of poliomyelitis caused by poliovirus types 1 and 3
Common side effects
- Vaccine-derived poliovirus (VDPV) shedding
- Mild gastrointestinal symptoms
- Fever
Key clinical trials
- Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines (PHASE1, PHASE2)
- Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants (PHASE3)
- Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV) (PHASE4)
- A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine (PHASE2)
- Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults (PHASE1)
- Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine (PHASE3)
- Evaluation of the Immunogenicity and Safety of Concomitant Administration of Novel Oral Polio Type 2 Vaccine and Bivalent Oral Polio Vaccine (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |